The company specializes in discovering and creating drugs that target Dravet syndrome, a severe and intractable form of epilepsy that affects infants. Epygenix Therapeutics uses genetic zebrafish models to develop their EPX series of compounds, which have the potential to transform the treatment of genetic epilepsies. By focusing on precision medicine, the company aims to improve the quality of life for patients and their families, who often struggle with the constant care required for these rare and devastating conditions.